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Abstract
Backround: The optimal antithrombotic treatment during a primary percutaneous coronary intervention (pPCI) is
not known. This single center registry study aims to assess the safety of a novel antithrombotic regimen combining
enoxaparine and prasugrel at presentation, followed by bivalirudin at the catheterisation laboratory.
Methods: All consecutive patients who underwent a pPCI were collected prospectively. The primary endpoint was
major bleeding within 30 days. The secondary endpoints were a composite of major adverse cardiovascular events
(MACE) consisting of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, a new target vessel
revascularisation and all-cause mortality at 30 days.
Results: Ninety-nine out of the total of 390 patients were treated according to the new regimen (protocol-treated
group). The rest received other antithrombotic treatment (non-protocol-treated group). The protocol-treated group
had a lower risk than the non-protocol-treated group according to the GRACE ischaemic (112 vs. 124, p = 0.002)
and CRUSADE bleeding scores (21 vs. 28, p < 0.0001). The incidences of bleeding were similar: severe GUSTO or
TIMI bleeding occurred in 0 % of the protocol-treated group and in 1.0 and 0.3 %, respectively, of the other group
(p = 0.311 for GUSTO and p = 0.559 for TIMI). The incidence of MACE in the groups was 6.1 and 10.7 %, respectively
(p = 0.178). The respective incidences of all-cause mortality were 5.1 and 9.6 % (p = 0.158).
Conclusions: Administration of the novel antithrombotic regimen seems to be safe.
Background
Primary percutaneous coronary intervention (pPCI) is
the preferred first-line treatment for acute ST- segment
elevation myocardial infarction (STEMI) [1]. Antithrom-
botic treatment is an essential part of the pPCI proced-
ure in enhancing the opening of the occluded coronary
artery as well as preventing peri- and post-procedural
thrombotic complications and late recurrent ischaemic
events. Peri-procedural stroke, for example, has been
recognised as an important life-limiting complication
[2]. The development of new antithrombotic agents has
been rapid over the last decade. The application of clopi-
dogrel and glycoprotein (GP) IIb/IIIa inhibitors in
addition to heparin and aspirin has been shown to de-
crease early and late adverse cardiac events with a con-
comitant and undesired increase in bleeding events [3–6].
Bleeding has been recognised as a major determinant of
cardiovascular death and adverse events in acute coronary
syndrome (ACS) patients [7].
Prasugrel is a novel thrombocyte receptor P2Y12 in-
hibitor, which has a more rapid, efficacious and consist-
ent antithombotic effect than clopidogrel [8, 9]. In the
TRITON TIMI-38 trial, prasugrel was more effective
than clopidogrel in reducing adverse cardiac events in
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both acute non-ST-elevation myocardial infarction and
STEMI patients [10]. However, the incidence of severe
bleeding events, especially in elderly and low-weight pa-
tients as well as those with prior ischaemic cerebrovas-
cular events was raised with prasugrel when compared
to clopidogrel.
Bivalirudin is an intravenously administered direct,
short-acting thrombin inhibitor [11]. In the HORIZONS-
AMI trial, it reduced severe bleeding events as well as
early and late net adverse events in STEMI patients when
compared to heparin plus GPIIb/IIIa-inhibitor, with an in-
crease in the incidence of early stent thromboses [12]. In
the EUROMAX study, bivalirudin started during transport
for pPCI was similarily associated with a reduction in
major bleeding events and an increase in early stent
thrombosis compared to heparin or enoxaparin with op-
tional GPIIb/IIIa inhibitor [13]. The recent HEAT-PPCI
compared heparin and bivalirudin in a randomised set-
tings; heparin reduced the incidence of major ischaemic
events with equal safety profile [14]. Importantly, the
other antithrombotic drugs used differed between the
studies.
Enoxaparine is an alternative to unfractionated hep-
arin. In the ATOLL trial, intravenous enoxaparine, in
comparison to heparin, was associated with fewer is-
chaemic events with similar bleeding rates for acute
STEMI patients undergoing pPCI [15].
No previous study has combined prehospital prasugrel
and enoxaparine with bivalirudin. We hypothesized that
using this combination of drugs might balance the risk
of early stent thrombosis and bleeding events in pPCI
patients. Thus, we report the results of our new anti-
thrombotic pPCI regimen including aspirin, a low-dose
enoxaparine i.v. bolus and prasugrel loading upon first
medical contact (FMC) combined with a bivalirudin in-
fusion initiated in the catheterisation laboratory.
Methods
Study patients and data collection
The present study took place in the Meilahti hospital,
responsible of all PCIs for STEMI in the Helsinki-
Uusimaa Hospital District of 1.5 million inhabitants. Ac-
cording to the new local STEMI guidelines launched on
1 November 2010, all acute STEMI patients referred to
pPCI should receive aspirin 250 mg, enoxaparine 30 mg
intravenously and prasugrel 60 mg upon FMC. The biva-
lirudin infusion (a bolus of 0.75 mg/kg followed by an
infusion of 1.75 mg/kg/h) should be started in the cath-
eter laboratory. After PCI, aspirin 100 mg daily should
be continued indefinitely and prasugrel 10 mg daily for
12 to 15 months. A lower prasugrel dosage of 5 mg
daily, or clopidogrel 75 mg daily instead of prasugrel, is
recommended for patients weighing under 60 kg or aged
over 75 years. Those with a previous stroke or transient
ischemic attack are recommended to continue with clo-
pidogrel 75 mg daily. When switching to clopidogrel, it
is advised to load the new drug at 300–600 mg the day
after prasugrel loading.
In order to assess the efficacy and safety of the new
antithrombotic regimen, we examined all acute STEMI
patients treated with pPCI in the Meilahti hospital be-
tween 1 January 2011 and 30 April 2012. The patients
were prospectively collected into a local STEMI registry.
All hospital files regarding the index STEMI hospitalisa-
tion and the following 30-day period were searched to
receive detailed data on patients risk profile, treatments
and clinical outcome. Mortality data was available for all
patients from the National Population Register Centre.
This was a registry study, which did not need an ap-
proval from the ethics committee. An informed consent
was not needed; no contact to the patient was taken in
this registry study and the data was anonymized and de-
identified prior to analysis. The study protocol was ap-
proved by the Helsinki-Uusimaa Hospital District. The
study was performed in accordance with the Declaration
of Helsinki.
The inclusion criteria were acute STEMI treated with
pPCI within the first 12 hours after symptom onset.
The criteria for a STEMI diagnosis were acute chest
pain (or equivalent) and 1) ST elevations of ≥ 2 mm
(≥1.5 mm for women) in at least two of the leads V1–3,
or 2) ST elevations of ≥1 mm in at least two other leads
(V4–6, V8–9, V4R, I, aVL, II, III, aVF), or 3) a new left
bundle branch block in ECG. Patients who received fi-
brinolysis were excluded from the study.
Definitions of study endpoints
The primary endpoint was major bleeding within 30 days.
Bleedings were classified and reported according to
GUSTO and TIMI criteria [16, 17]. The secondary end-
points were 1) a composite of major adverse cardiovas-
cular events (MACE) consisting of cardiovascular death,
non-fatal myocardial infarction, non-fatal stroke and a
new target vessel revascularisation procedure, and 2) all-
cause mortality at 30 days. Myocardial infarction was de-
fined according to current international guidelines [18].
Stroke was defined as any focal neurological deficit of is-
chaemic or haemorrhagic origin lasting for longer than
24 hours.
Statistical analysis
The follow-up of the acute STEMI patients who received
the guideline-defined adjuvant treatment was analysed
primarily without a control group. Secondarily, a com-
parison with pPCI patients who had received other adju-
vant treatment was performed. Continuous variables are
described using medians, means and standard deviations
(SD). Categorical variables are described with absolute
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(number) and relative (percentage) frequency distribu-
tion. Statistical analyses across the groups were done
with a chi-square test for categorical variables and
ANOVA for continuous variables. A Cox regression sur-
vival analysis was performed for MACE using age, sex,
access site, thrombectomy, antithrombotic treatment as
well as GRACE and CRUSADE scores as covariates.
IBM SPSS Statistics version 19.0 was used for all
analyses.
Results
In total, 390 acute STEMI patients fulfilling the study
criteria were identified within the study period. Ninety-
nine patients (25 %) received the complete guideline-
defined antithrombotic treatment with aspirin, a bolus
of i.v. enoxaparine and a loading dose of prasugrel at
presentation followed by a bivalirudin infusion at the
catheter laboratory (protocol-treated group). The
remaining 291 patients received some other combination
of antithrombotic agents (non-protocol treated group).
The patients in the protocol-treated group were sig-
nificantly younger and less likely to be on warfarin
treatment at presentation than the patients in the
non-protocol-treated group (Table 1). There was a
trend towards a higher prevalence of diabetes and
prior coronary artery bypass operations in the non-
protocol-treated group. Smoking was more common
in the protocol-treated group. Other cardiovascular
risk factors or prior cardiovascular disease did not
vary significantly across the groups (Table 1). At pres-
entation, according to the GRACE and CRUSADE
score calculations, the predicted risk of short- and
long-term adverse cardiovascular events and in-
hospital bleeding events was significantly higher in the
non-protocol-treated group (Table 2). The proportion
of patients presenting with acute heart failure was also
significantly higher in the non-protocol-treated group.
Sixteen percent of patients in the non-protocol-treated
group had normal coronary arteries or only modest cor-
onary artery lesions, whereas all patients in the protocol-
treated group had significant coronary artery disease.
Consequently, normal coronary artery flow before PCI
was more frequent in the non-protocol-treated group
(Table 2). However, the prevalence of left-main or tree-
vessel disease did not vary significantly across the
Table 1 Baseline characteristics, cardiovascular risk factors, prior
cardiovascular diseases, revascularisations and medications in
the protocol and non-protocol treated groups
Protocol Non-protocol p
n = 99 n = 291
Mean age, years, mean (SD) 59.5 (14) 66.1 (14) <0.001
Age > 75 years, n (%) 11 (11.1) 97 (33.3) <0.001
Male sex, n (%) 74 (74.7) 198 (68.0) 0.210
Diabetes, n (%) 13 (13.1) 64 (22.0) 0.056
Current smoker, n (%) 50 (50.5) 95 (32.6) 0.001
Hypertension, n (%) 49 (49.5) 158 (54.3) 0.408
Dyslipidaemia, n (%) 39 (39.4) 123 (42.3) 0.616
Renal dysfunctiona, n (%) 3 (3.0) 11 (3.8) 0.729
Peripheral vascular disease, n (%) 4 (4.0) 14 (4.8) 0.752
Previous myocardial infarction, n (%) 9 (9.1) 32 (11.0) 0.593
Previous stroke, n (%) 4 (4.0) 21 (7.2) 0.265
Previous CABG, n (%) 1 (1.0) 15 (5.2) 0.073
Previous PCI, n (%) 10 (10.1) 39 (13.4) 0.392
Aspirin, n (%) 21 (21.2) 81 (27.8) 0.195
P2Y12-receptor inhibitor, n (%) 2 (2.0) 11 (3.8) 0.399
Warfarin, n (%) 2 (2.0) 37 (12.7) 0.002
CABG coronary artery by-pass intervention, PCI percutaneous coronary
intervention
aestimated glomerular filtration rate <60 ml/min/1.73 m2
Table 2 Clinical characteristics at presentation, coronary
angiography and revascularisation procedures in the protocol
and non-protocol treated groups
Protocol Non-protocol p-value
n = 99 n = 291
Anterior STEMI, n (%) 43 (43.4) 138 (47.4) 0.492
GRACE score, mean (SD) 112 (31) 124 (36) 0.002
CRUSADE score, mean (SD) 21 (13) 28(16) <0.0001
Killip class > I, n (%) 8 (8.1) 62 (21.5) 0.003
Killip class IV, n (%) 2 (2.0) 13 (4.5) 0.270
eGFR ml/min, mean (SD) 103 (40) 90 (41) 0.009
Hemoglobin g/l, mean (SD) 135 (15) 133 (18) 0.283
Weight kg, mean (SD) 81 (16) 80 (17) 0.644
Angiography
Radialis access, n (%) 33 (33.3) 77 (26.6) 0.196
3VD, n (%) 14 (14.1) 56 (19.2) 0.253
LMD, n (%) 2 (2.0) 16 (5.5) 0.154
TIMI flow grade 0–1, n (%) 68 (70.1) 119 (57.2) 0.031
TIMI flow grade 3, n (%) 15 (15.5) 58 (27.9) 0.018
Normal findings or modest
coronary artery disease
0 (0) 46 (16.0) <0.0001
PCI, n (%) 99 (100) 205 (70.4) <0.0001
Use of stents (of all PCI), n (%) 91 (91.9) 187 (91.2) 0.838
Use of DES (of stents), n (%) 13 (14.3) 24 (12.8) 0.738
Thrombectomy (of all PCI), n (%) 53 (53.5) 68 (33.2) 0.001
TIMI flow grade 0–1 post PCI, n (%) 0 (0) 8 (3.8) 0.053
TIMI flow grade 3 post PCI, n (%) 89 (91.8) 182 (85.8) 0.143
CABG, n (%) 2 (2.0) 17 (5.8) 0.127
eGFR glomerular filtration rate estimated by Cockcroft-Gault formula, 3VD three
vessel coronary artery disease, LMD left main coronary artery disease, LAD-PCI
percutaneous coronary intervention to left anterior descending artery, DES
drug-eluting stent, CABG coronary artery bypass graft surgery
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groups. A percutaneous coronary intervention was per-
formed more often in the protocol-treated group. The
use of bare metal or drug-eluting stents among the PCI-
treated patients did not vary significantly across the
groups. However, thrombectomy was more common in
the protocol-treated group. There were no significant
differences in post-PCI coronary artery flow between the
groups. The median total ischaemic time (delay from
symptom onset to PCI) was 300 min. and 264 min. in
the protocol-treated and non-protocol-treated groups,
respectively (p = 0.165 between the groups).
The use of glycoprotein-inhibitors was uncommon in
the protocol-treated group, whereas they were used in
approximately one quarter of the patients in the non-
protocol-treated group (Table 3). Clopidogrel was used
frequently in the non-protocol-treated group.
Bleeding events were rare in the overall population,
and their occurrence did not differ between the groups
(Table 4). None of the patients suffered intracranial or
fatal bleedings during the study period. Major adverse
cardiac events and deaths were observed more fre-
quently in the non-protocol-treated group, but the
difference across the groups was not statistically sig-
nificant (Table 4). In the multivariable Cox analysis for
MACE, high GRACE and CRUSADE scores were the
only variables associated with worse prognosis (data
not shown).
At discharge, prasugrel was used in 77 and 26 % of
the patients in the protocol-treated and non-protocol-
treated groups, respectively, (p < 0.0001 between the
groups) and clopidogrel in 17 and 46 % of the patients,
respectively (p < 0.001). Statins were used in 94 and
82 % (p = 0.004), beta blockers in 89 and 78 % (p = 0.04)
and angiotensin convertase inhibitors or angiotensin II re-
ceptor blockers in 81 and 65 % of the patients (p = 0.003),
respectively.
Discussion
Bleeding events
In this paper, we report the results on STEMI patients
treated with a novel antithrombotic regimen combin-
ing aspirin, an i.v. enoxaparine bolus and a prasugrel
loading dose at presentation, followed by bivalirudin
infusion at the catheterisation laboratory. To the best
of our knowledge, no previous study has used the
same adjuvant therapy. Our principal finding is that
the administration of the new regimen is safe. None of
the protocol-treated patients suffered a severe bleed-
ing event during the 30-day follow-up. The incidence
of mild to moderate bleeding events was only 3 % in
that group. This outcome was favourable compared to
the CRUSADE-score-based estimation of 5.5 % in-
hospital incidence of bleeding events in the protocol
treated group. On the other hand, the incidence of se-
vere bleeding events was low also in the non-protocol-
treated group as well, and there were no significant
differences in bleeding events between the groups.
Therefore, our findings support the concept that biva-
lirudin can be combined to low-dose low-molecular
heparin without increasing bleeding complications.
The safety of bivalirudin compared to heparin plus GP
IIb/IIIa-inhibitors in pPCI-patients is supported by two
major trials: HORIZONS-AMI and EUROMAX [12, 13].
The incidence of net adverse and severe bleeding events
was reduced with bivalirudin in both trials. In
HORIZONS-AMI, bivalirudin was compared to heparin
plus GP-inhibitors with almost all patients having a clo-
pidogrel loading at the time of admission. Heparin was
given in 68 % in the bivalirudin group. In the Euromax
study, 51 % of the patients had a clopidogrel loading as
soon as possible and the rest received either prasugrel
(30 %) or ticagrelor (19 %). Heparin was used in only
2.2 % in the bivalirudin group.
Table 3 Antithrombotic treatment in the protocol (n = 99) and
non-protocol (n = 291) treated groups
Protocol,
n (%)
Non-protocol,
n (%)
P-value
First medical contact
Aspirin 99 (100) 257 (88.3) <0.0001
Prasugrel loading dose 99 (100) 139 (47.8) <0.0001
Clopidogrel loading dose 1(1.0) 116 (39.9) <0.0001
Enoxaparin bolus i.v. 99 (100) 192 (66.0) <0.0001
Glycoprotein IIb/IIIa inhibitor 0 (0) 15 (5.2) 0.021
Catheter laboratorio
Bivalirudin 99 (100) 36 (12.4) <0.0001
Glycoprotein IIb/IIIa inhibitor 6 (6.1) 79 (27.1) <0.0001
Enoxaparin i.v. 9 (9.1) 56 (19.2) 0.019
Unfractionated heparin 0 (0) 7 (2.4) 0.119
Table 4 Major adverse cardiac events, mortality and bleeding
events at 30 days in the protocol (n = 99) and non-protocol
(n = 291) treated groups
Protocol Non-protocol p-value
n (%) n (%)
MACE 6 (6.1) 31 (10.7) 0.178
Cardiovascular death 4 (4.0) 26 (8.9) 0.114
Non-fatal myocardial infarction 0 (0) 1 (0.3) 0.559
Non-fatal stroke 1 (1.0) 4 (1.4) 0.781
Target vessel revascularisation 1 (1.0) 3 (1.0) 0.986
Death from any cause 5 (5.1) 28 (9.6) 0.158
Severe GUSTO bleeding 0 (0) 3 (1.0) 0.311
Mild or minor GUSTO bleeding 3 (3.0) 6 (2.1) 0.579
Major TIMI bleeding 0 (0) 1 (0.3) 0.559
Minor or minimal TIMI bleeding 2 (2.0) 4 (1.4) 0.652
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Adverse events
None of the protocol-treated patients suffered from
stent thrombosis or recurrent myocardial infarction. The
non-protocol group presented one stent thrombosis and
one myocardial infarction within a month. The incidence
of MACE and all-cause death in the protocol-treated
group was 6.1 and 5.1 percent, respectively. These num-
bers are comparable to MACE and mortality figures re-
cently published based on the French and Swedish
STEMI registries [19, 20]. From this perspective, the
new anti-thrombotic regimen also seems to be efficient.
The non-protocol group presented with a higher risk
profile (older age, warfarin usage, higher GRACE and
CRUSADE scores, higher Killip class at presentation,
worse renal function) than those treated with the new
protocol. However, the number of endpoints did not dif-
fer between the treatment groups, which is probably due
to the low number of adverse events. The Cox regres-
sion analysis presented the GRACE and CRUSADE
scores – which integrate patient-related information
from several angles – as the only variables predicting
poor prognosis.
The rate of early stent thromboses was increased with
bivalirudin in both the HORIZONS-AMI and EURO-
MAX trials. This may be partly due to an inconsistent
action of clopidogrel used widely in both trials. Import-
antly, in HORIZONS-AMI, those patients who had re-
ceived the heparin bolus prior to randomisation had a
lower risk of stent thrombosis than those without pre-
randomisation heparin [21]. In EUROMAX, only 2 % of
the bivalirudin treated patients were protected by hep-
arin. However, in our study, the usage of prasugrel and
enoxaparine with bivalirudin might have protected pa-
tients against stent thromboses.
The recent HEAT-PPCI study randomised STEMI pa-
tients to receive either bivalirudin or heparin infusion,
with provisional GP IIb/IIIa inhibitors used in only 13-
15 % of the patients in each group [14]. Only 11 % re-
ceived clopidogrel, as prasugrel (27 %) and ticagrelor
(62 %) were clearly more common. The rate of major
adverse events during 28 day follow-up was significantly
higher with bivalirudin mainly due to increased rate of
stent thromboses. The bleeding rates did not differ
across the groups. This might be due to low usage of GP
IIb/IIIa inhibitors also in the heparin arm. Of note, the
patients in the bivalirudin group were not protected with
either heparin or enoxaparine.
Our hypothesis was that combining pre-hospital enox-
aparine and prasugrel with bivalirudin during the pPCI
procedure might balance the risk of bleeding and early
stent thromboses. The observed low incidence of bleed-
ing events and the lack of stent thromboses and recur-
rent myocardial infarctions in the protocol-treated
patients support the hypothesis. We replaced heparin,
which was widely used in the bivalirudin arm in the
HORIZONS-AMI trial, by a low dose of enoxaparine at
FMC without any evident rise in bleeding events.
Adoption of the new protocol
The rate of adoption of the new local guidelines in daily
practice was clearly lower than we expected. The devia-
tions were mostly due to the omission of prasugrel and,
particularly, bivalirudin. Firstly, only half of the patients
in the non-protocol-treated group received prasugrel at
FMC. This might reflect the fact that we started the sur-
vey period relatively soon, two months after the guide-
line implementation. Patients were referred to our pPCI
centre from a relatively large area with different emer-
gency medical system organisations, a setting that may
have compromised the early guideline implementation
process. Secondly, the utilisation of bivalirudin in the
catheter laboratory was low in the non-protocol-treated
group. Operators seemed to prefer to see the angio-
graphic result before deciding whether to use bivaliru-
din. This policy is reflected as a higher incidence of
normal angiographic findings in the non-protocol-
treated groups.
Limitations
We observed unexpectedly low bleeding rates in both
treatment groups. Despite the differences in GRACE and
CRUSADE scores the rate of adverse events did not dif-
fer across the groups. These findings might be related to
the relatively small sample size and the non-randomised
trial design, which are limitations to our study. Another
limitation is the low penetration of the guidelines in
daily practice, leaving open questions on the usability of
the new regimen in unselected patient populations.
Conclusions
The present study offers preliminary findings on a new
antithrombotic regimen combining low-dose enoxapar-
ine, prasugrel and bivalirudin in STEMI patients. The
data are promising and suggest that the regimen is both
safe and efficient, but the results need to be confirmed
in randomised studies.
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